"Cholangitis, Sclerosing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.
| Descriptor ID |
D015209
|
| MeSH Number(s) |
C06.130.120.200.110
|
| Concept/Terms |
Cholangitis, Sclerosing- Cholangitis, Sclerosing
- Cholangitides, Sclerosing
- Sclerosing Cholangitides
- Sclerosing Cholangitis
- Cholangiitis, Sclerosing
- Cholangiitides, Sclerosing
- Sclerosing Cholangiitides
- Sclerosing Cholangiitis
Primary Sclerosing Cholangitis- Primary Sclerosing Cholangitis
- Cholangitides, Primary Sclerosing
- Primary Sclerosing Cholangitides
- Sclerosing Cholangitides, Primary
- Sclerosing Cholangitis, Primary
- Cholangitis, Primary Sclerosing
|
Below are MeSH descriptors whose meaning is more general than "Cholangitis, Sclerosing".
Below are MeSH descriptors whose meaning is more specific than "Cholangitis, Sclerosing".
This graph shows the total number of publications written about "Cholangitis, Sclerosing" by people in this website by year, and whether "Cholangitis, Sclerosing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 5 | 0 | 5 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 2 | 3 |
| 2021 | 7 | 0 | 7 |
| 2022 | 1 | 0 | 1 |
| 2023 | 3 | 0 | 3 |
| 2024 | 5 | 0 | 5 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholangitis, Sclerosing" by people in Profiles.
-
Statin Use Is Associated With Protection Against Acute Cholangitis in Patients With Primary Sclerosing Cholangitis: A Multicenter Retrospective Cohort Study. Clin Transl Gastroenterol. 2025 Apr 01; 16(4):e00816.
-
Epigenetic disease markers in primary sclerosing cholangitis and primary biliary cholangitis-methylomics of cholestatic liver disease. Hepatol Commun. 2024 08 01; 8(8).
-
Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune-mediated liver injury. Hepatology. 2025 Oct 01; 82(4):949-959.
-
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther. 2024 05; 59(10):1236-1247.
-
Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts. Gastroenterology. 2024 06; 166(6):995-1019.
-
Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply. Aliment Pharmacol Ther. 2024 01; 59(2):282.
-
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
-
Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data. BMC Gastroenterol. 2023 Apr 19; 23(1):129.
-
Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis. Nat Commun. 2023 02 24; 14(1):1069.
-
Reply: Insurance should cover vancomycin for primary sclerosing cholangitis. Hepatology. 2023 06 01; 77(6):E176-E177.